Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 50-75 lat
- •Po menopauzie (12 miesięcy bez menstruacji)
- •Ma przynajmniej jeden jajnik
- •Bez historii raka, bez chemioterapii i radioterapii przez ostatnie 12 miesięcy
- •Chęć powrotu na coroczne badania krwi CA-125
- •Chęć wykonania ultrasnomu przez pochwę jeśli będzie wskazane
- •Posiada swojego ginekologa lub lekarza do dalszej opieki
✗ Disqualifies
- •Kobieta poniżej 50 lat lub powyżej 75 lat
- •Problemy psychiczne lub psychologiczne uniemożliwiające świadomą zgodę na uczestnictwo
- •Usunięte oba jajniki
- •Aktywny nowotwór (poza jajnikami)
- •Wysoke ryzyko raka jajnika ze względu na predyspozycję rodzinną (mutacje BRCA1/BRCA2, historia raka w rodzinie)
- •Żydowskie pochodzenie ashkenazyjskie z historią raka jajnika lub piersi w rodzinie
Simplified criteria — AI translation
Trial details
- Minimum age
- 50 Years
- Maximum age
- 74 Years
- Last updated (source)
- October 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (12)
Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine
Miami, United States
John Stoddard Cancer Center
Des Moines, United States
University of Minnesota
Minneapolis, United States
Carol G. Simon Cancer Center / Atlantic Health
Morristown, United States
University of Rochester Medical Center
Rochester, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Women's and Infant's Hospital
Providence, United States
The University of Texas at Austin
Austin, United States
University of Texas (UT) Southwestern Medical Center
Dallas, United States
University of Texas MD Anderson Cancer Center
Houston, United States
Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA)
Houston, United States
UT Health Science Center San Antonio
San Antonio, United States
Trial contact
Gwen H. Corrigan
Study Coordinator MD Anderson
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.